Anjali Vasavada

Anjali Vasavada

Auto-generated profile, based on publicly available information

Anjali Vasavada

Department of Epidemiology, University of Washington School of Public Health, Seattle, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2020 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
Junaid NabiJunaid Nabi
Junaid Nabi
ECEugene B Cone
Eugene B Cone
AVAnjali Vasavada
Anjali Vasavada
MSMaxine Sun
Maxine Sun
KKKerry L Kilbridge
Kerry L Kilbridge
MLMuhieddine Labban
Muhieddine Labban
Background: Androgen deprivation therapy (ADT) increases the risk of metabolic adverse effects among patients with prostate cancer. The transformative impact of mobile health (mHealth) apps may benefit men managing activity and nutrition at home. Objective: This study aimed to evaluate the usability and patient experience of a newly developed mHealth app among prostate cancer patients on ADT and physicians’ beliefs about the potential benefits of using this app. Methods: This study took place over 2 months, beginning in March 2019. A sample of 5 patients (age 45-75 years) initiating ADT participated in a semistructured focus group discussion with a facilitator. The study participants also included 5 specialist physicians who provided in-depth interviews. An institutional review board–approved script was used to guide both the focus group and physician interviews. Usability was tested through specific scenarios presented to the patients, including downloading the mHealth app, entering information on physical activity and meals, and navigating the app. The focus group and interviews were audio recorded and transcribed. Content analysis was used to analyze the transcripts iteratively and exhaustively. Thematic discrepancies between reviewers were resolved through consensus. Results: The mean age of the patients was 62 years. This group included 4 White and 1 Latin American patients. The physician specialists included 2 urologists, 2 medical oncologists, and 1 radiation oncologist. Analyses revealed that the patients appreciated the holistic care enabled by the app. Difficulties were observed with registration of the app among 60% (3/5) of the patients; however, all the patients were able to input information about their physical activity and navigate the options within the app. Most patients (4/5, 80%) were able to input data on their recent meal. Among the health care physicians, the dominant themes reflected in the interviews included undermining of patients ability to use technology, patients’ fear of technology, and concern for the ability of older patients to access technology. Conclusions: The patients reported an overall positive experience of using an mHealth app to record and track diet and exercise. Usability was observed to be an important factor for adoption and was determined by ease of registration and use, intuitive appearance of the app, and focus on holistic cancer care. The physicians believed that the app was easy to use but raised concerns about usability among older men who may not typically use smartphone apps.

2 September 2025
Verified
Other
Open access
FFFaiza Faria
Faiza Faria
SHStephen E. Hawes
Stephen E. Hawes
JLJohn Lin
John Lin
JSJeffrey Schouten
Jeffrey Schouten
HKHelen C. Stankiewicz Karita
Helen C. Stankiewicz Karita
RWRachel Winer
Rachel Winer
Supplementary Table S1 shows HPV subtypes detected with HRA HSIL disease extent

13 May 2020 in JMIR Preprints
Verified
Preprint
Open access
Junaid NabiJunaid Nabi
Junaid Nabi
ECEugene B Cone
Eugene B Cone
AVAnjali Vasavada
Anjali Vasavada
MSMaxine Sun
Maxine Sun
KKKerry L Kilbridge
Kerry L Kilbridge
MLMuhieddine Labban
Muhieddine Labban
BACKGROUND Androgen deprivation therapy (ADT) increases the risk of metabolic adverse effects among patients with prostate cancer. The transformative impact of mobile health (mHealth) apps may benefit men managing activity and nutrition at home. OBJECTIVE This study aimed to evaluate the usability and patient experience of a newly developed mHealth app among prostate cancer patients on ADT and physicians’ beliefs about the potential benefits of using this app. METHODS This study took place over 2 months, beginning in March 2019. A sample of 5 patients (age 45-75 years) initiating ADT participated in a semistructured focus group discussion with a facilitator. The study participants also included 5 specialist physicians who provided in-depth interviews. An institutional review board–approved script was used to guide both the focus group and physician interviews. Usability was tested through specific scenarios presented to the patients, including downloading the mHealth app, entering information on physical activity and meals, and navigating the app. The focus group and interviews were audio recorded and transcribed. Content analysis was used to analyze the transcripts iteratively and exhaustively. Thematic discrepancies between reviewers were resolved through consensus. RESULTS The mean age of the patients was 62 years. This group included 4 White and 1 Latin American patients. The physician specialists included 2 urologists, 2 medical oncologists, and 1 radiation oncologist. Analyses revealed that the patients appreciated the holistic care enabled by the app. Difficulties were observed with registration of the app among 60% (3/5) of the patients; however, all the patients were able to input information about their physical activity and navigate the options within the app. Most patients (4/5, 80%) were able to input data on their recent meal. Among the health care physicians, the dominant themes reflected in the interviews included undermining of patients ability to use technology, patients’ fear of technology, and concern for the ability of older patients to access technology. CONCLUSIONS The patients reported an overall positive experience of using an mHealth app to record and track diet and exercise. Usability was observed to be an important factor for adoption and was determined by ease of registration and use, intuitive appearance of the app, and focus on holistic cancer care. The physicians believed that the app was easy to use but raised concerns about usability among older men who may not typically use smartphone apps.

11 July 2025 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
FFFaiza Faria
Faiza Faria
SHStephen E. Hawes
Stephen E. Hawes
JLJohn Lin
John Lin
JSJeffrey Schouten
Jeffrey Schouten
HKHelen C. Stankiewicz Karita
Helen C. Stankiewicz Karita
RWRachel Winer
Rachel Winer
Background: Molecular biomarkers could enhance anal cancer screening accuracy in people living with human immunodeficiency virus. We assessed the performance of human papillomavirus (HPV) 16/18 E6 oncoprotein in detecting anal high-grade squamous intraepithelial lesions (HSIL) in men living with human immunodeficiency virus. Methods: We analyzed clinical data from 125 clinic visits of 82 men living with human immunodeficiency virus who underwent high-resolution anoscopy in Seattle, Washington (2015–2016), including the presence and extent of HSIL. Anal brush specimens were tested for high-risk HPV DNA, with HPV-16/18–positive samples further tested for E6 oncoprotein. Sensitivity, specificity, positive predictive value, and negative predictive value of HPV-16/18 E6 oncoprotein for HSIL were calculated, along with prevalence ratios with 95% confidence intervals. Results: Forty-eight (38.4%) samples were HPV-16/18 positive, including three E6 positive. Forty-nine (39.2%) samples had corresponding HSIL. Specificity and positive predictive value of HPV-16/18 E6 for HSIL was 100%, and the prevalence ratio was 7.33 (95% confidence interval, 2.44–22.07) for HPV-16/18 E6–positive versus high-risk HPV–negative samples. Sensitivity for HSIL, however, was only 6.1%, with a moderate negative predictive value (62.3%). Two of four persons with HSILs with >75% disease extent had corresponding HPV-16/18 E6–positive samples, whereas none of 30 persons with <25% extent did. Conclusions: The HPV-16/18 E6 oncoprotein has potential utility as a triage biomarker for identifying and prioritizing lesions at the highest risk for progression. Impact: People living with human immunodeficiency virus are at an increased risk of anal cancer and would benefit from improved screening methods. Further research may elucidate the role of HPV-16/18 E6 oncoprotein in anal cancer prevention, alone or combined with other biomarkers.

21 July 2026 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
AVAnjali Vasavada
Anjali Vasavada
LPLorella Palazzo
Lorella Palazzo
CLCasey Luce
Casey Luce
MSMagali Sanchez
Magali Sanchez
MTMatthew Triplette
Matthew Triplette
KWKaren J. Wernli
Karen J. Wernli
Older adults bear a disproportionate cancer burden but remain underrepresented in digital health intervention trials compared to younger counterparts. Sinc

2 September 2025
Verified
Other
Open access
FFFaiza Faria
Faiza Faria
SHStephen E. Hawes
Stephen E. Hawes
JLJohn Lin
John Lin
JSJeffrey Schouten
Jeffrey Schouten
HKHelen C. Stankiewicz Karita
Helen C. Stankiewicz Karita
RWRachel Winer
Rachel Winer
Supplementary Figure S1 is a flowchart Flowchart showing participant enrollment, sample inclusion, and clinical outcomes.